SCHEMBL13610890

SCHEMBL13610890

Nc1ccc(Oc2ccnc([N+](=O)[O-])c2OCc2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.47
RAB9A P51151 4/20 0.47
MEN1 O00255 4/20 0.47
NPC1 O15118 3/20 0.47
ATM Q13315 1/20 0.47
MAPT P10636 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
GAA P10253 1/20 0.47
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MGMT P16455 1/20 0.41
ALDH1A1 P00352 2/20 0.39
CYP19A1 P11511 2/20 0.38
CYP11B1 P15538 2/20 0.38
CYP11B2 P19099 2/20 0.38
PDE7A Q13946 2/20 0.38
LTA4H P09960 1/20 0.37
MAPK14 Q16539 1/20 0.37
CA12 O43570 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13610887 0.81 MAPT (0.40) KMT2ARAB9AMEN1NPC1MAPT
SCHEMBL8566190 0.77 KMT2A (0.58) KMT2ARAB9AMEN1NPC1ATM
SCHEMBL13603241 0.75 ALDH1A1 (0.46) KMT2ARAB9AMEN1NPC1MAPT
SCHEMBL13603249 0.75 KMT2A (0.46) KMT2AMEN1MAPTL3MBTL1ALDH1A1
SCHEMBL1793473 0.75 KMT2A (0.51) KMT2ARAB9AMEN1NPC1ATM
SCHEMBL5344847 0.72 MEN1 (0.50) KMT2ARAB9AMEN1NPC1ATM
SCHEMBL811068 0.72 MAPT (0.56) KMT2ARAB9AMEN1NPC1ATM
SCHEMBL5531567 0.72 KMT2A (0.61) KMT2ARAB9AMEN1NPC1ATM
SCHEMBL12616262 0.72 PPIA (0.45) KMT2AMEN1ALDH1A1
SCHEMBL16919130 0.72 KMT2A (0.48) KMT2ARAB9AMEN1NPC1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7625922-B2 Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-12-01 US disclosed
US-20070287838-A1 Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287838-A1 Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds NR2E1, NR0B1, BRAF KMT2A 2007/4885RAB9A 2617/4885MEN1 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.